Lack of early symptom improvement is not predictive of final responder status Lack of early symptom improvement is not predictive of final responder status
View post:
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation
Read the original:
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
2023 ANNUAL RESULTS
Read more:
EUROBIO SCIENTIFIC: 2023 ANNUAL RESULTS
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers
The rest is here:
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR...
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
Continue reading here:
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung...
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up
Read the original post:
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up
SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.
See the rest here:
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
View post:
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations. Mr. Nassif joins Pharvaris with more than 30 years of experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal, and capital allocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies.
Read the rest here:
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
Go here to see the original:
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update